Literature DB >> 21303834

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations.

R Cervera1, M G Tektonidou, G Espinosa, A R Cabral, E B González, D Erkan, S Vadya, H E Adrogué, M Solomon, G Zandman-Goddard, Y Shoenfeld.   

Abstract

The objectives of the 'Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations' were to assess the clinical utility of the international consensus statement on classification criteria and treatment guidelines for the catastrophic APS, to identify and grade the studies that analyze the relationship between the antiphospholipid antibodies and the non-criteria APS manifestations, and to present the current evidence regarding the accuracy of these non-criteria APS manifestations for the detection of patients with APS. This article summarizes the studies analyzed on thrombocytopenia and skin manifestations, and presents the recommendations elaborated by the Task Force after this analysis.

Entities:  

Mesh:

Year:  2011        PMID: 21303834     DOI: 10.1177/0961203310395052

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  20 in total

Review 1.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

2.  Management of myocardial infarction in immune thrombocytopenic purpura with anti-phospholipid antibodies.

Authors:  Rie Tabata; Chiharu Tabata; Yoshio Kita
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

Review 3.  The significance and management of thrombocytopenia in antiphospholipid syndrome.

Authors:  Bahar Artim-Esen; Reyhan Diz-Küçükkaya; Murat İnanç
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 4.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

5.  Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance.

Authors:  Marie A Hollenhorst; Hanny Al-Samkari; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

Review 6.  Clinical assessment and management of cytopenias in lupus patients.

Authors:  Alana B Levine; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

7.  Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome.

Authors:  Ayten Yazıcı
Journal:  Eur J Rheumatol       Date:  2020-10

8.  Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications.

Authors:  Gerardo B Vieregge; Thomas J Harrington; David M Andrews; Maria F Carpintero; Dollie F Green; Ali Nayer
Journal:  Case Rep Med       Date:  2013-12-09

9.  Antiphospholipid syndrome-associated nephropathy: Current concepts.

Authors:  Hamid Nasri
Journal:  J Renal Inj Prev       Date:  2013-03-01

10.  Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report.

Authors:  Malgorzata Biernacka-Zielinska; Joanna Lipinska; Joanna Szymanska-Kaluza; Jerzy Stanczyk; Elzbieta Smolewska
Journal:  J Med Case Rep       Date:  2013-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.